Lung Cancer Clinical Trial

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned

Summary

The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if patients feel better while taking pemetrexed

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of small cell lung cancer
One prior treatment with chemotherapy or immunotherapy with greater than 3 weeks since the prior treatment
At least 18 years of age
Estimated life expectancy of at least 12 weeks
Ambulatory and capable of self-care(eg, up and about greater than 50% of waking hours)

Exclusion Criteria:

Have received treatment within the last 30 days with a drug that has not received FDA approval for any indication
Less than 2 weeks from radiation therapy
Other serious illness that would compromise the safety of the patient
Most second primary malignancies treated less than 5 years previously

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT00191750

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Aurora Colorado, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Chapel Hill North Carolina, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Dallas Texas, , United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT00191750

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider